Democratic Republic of Congo vs Gabon: Average cost of drugs for extensively drug-resistant tuberculosis
Democratic Republic of Congo
1,102 constant 2022 US$
in 2024
Gabon
995 constant 2022 US$
in 2024
Democratic Republic of Congo rank
41st
Gabon rank
42nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Democratic Republic of Congo
- Gabon
How they compare
Democratic Republic of Congo currently reports 1,102 constant 2022 US$ against 995 constant 2022 US$ in Gabon, a difference of 107 constant 2022 US$.
That makes Democratic Republic of Congo's figure about 1.1 times Gabon's.
The two have swapped places 2 times across 5 shared years of data; in 2020 it was Democratic Republic of Congo ahead.
Democratic Republic of Congo ranks 41st and Gabon ranks 42nd of 56 countries.
Gabon has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Democratic Republic of Congo or Gabon?
- Democratic Republic of Congo, at 1,102 constant 2022 US$ against 995 constant 2022 US$ in Gabon as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Democratic Republic of Congo and Gabon?
- 107 constant 2022 US$, with Democratic Republic of Congo ahead.
- How many years of comparable data are there for Democratic Republic of Congo and Gabon?
- 5 years are reported by both, from 2020 to 2024.
- How do Democratic Republic of Congo and Gabon rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Democratic Republic of Congo ranks 41st and Gabon ranks 42nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.